Repligen To Acquire BioLife Solutions For $1.5 Billion
Repligen (RGEN) agreed to acquire BioLife Solutions for about $1.5B enterprise value in a cash-and-stock deal. BioLife holders will get $11.25 cash and 0.1442 Repligen shares per share, a 24% premium. Repligen expects adjusted EPS contribution of at least $0.05 (year 1) and $0.25 (year 2), plus $20M synergies (year 1) and $30M (year 2). Closing is expected in Q4 2026.
How this was made
The 30-second read
Why it matters
Definitive M&A terms with a stated premium, consideration mix, and quantified synergy and EPS contribution targets create actionable repricing and deal-arb considerations for both RGEN and BLI.
Market read
A $1.5B definitive acquisition with quantified synergies and EPS contribution targets is likely to drive immediate deal-spread and valuation repricing.
What to watch
Key sensitivities are regulatory clearance timing, BioLife shareholder approval, and how the 64% stock consideration affects RGEN dilution and post-close valuation versus the implied $31 per-share announcement value.
Background
Repligen is expanding into cell and gene therapy biopreservation consumables via the acquisition of BioLife’s CryoStor platform.
Ticker impact
Repligen agreed to acquire BioLife Solutions for about $1.5B, issuing 0.1442 shares plus $11.25 cash per BioLife share.
Likely positive bias for RGEN on deal announcement, with volatility around financing, regulatory, and shareholder-approval milestones.
The article discloses definitive M&A terms, consideration mix (64% stock, 36% cash), funding source (cash on hand), and quantified synergy and EPS contribution targets.
Market effects
Strengthens consolidation in cell and gene therapy manufacturing enablement, potentially increasing competitive pressure on biopreservation and consumables providers.
Highlights Asia-Pacific commercial reach as a stated benefit, which may shift attention to regional distribution partners and customers.
Could influence global C> supply-chain dynamics by bundling biopreservation consumables with upstream processing technologies.
Counterpoint
The deal’s accretion and synergy targets may be optimistic; execution risk in integrating consumables and manufacturing/supply chain improvements could pressure the stock if milestones slip.
Key entities
- companyRepligen
Acquirer entering a definitive agreement to buy BioLife Solutions for about $1.5B in cash-and-stock.
- companyBioLife Solutions
Target whose shareholders receive $11.25 cash and 0.1442 RGEN shares per share, reflecting a 24% premium.
- productCryoStor
Biopreservation media platform used to maintain cell health during freezing, storage, and transportation.
